Resource Summary Report

Generated by ASWG on Aug 9, 2026

CD3

RRID:AB_2890105
Type: Antibody

Proper Citation

ZSGB-Bio Cat# ZM-0417, RRID:AB_2890105

Antibody Information

URL: http://antibodyregistry.org/AB_2890105

Proper Citation: ZSGB-Bio Cat# ZM-0417, RRID:AB_2890105

Target Antigen: CD3

Clonality: monoclonal

Comments: Applications: IHC

Antibody Name: CD3

Description: This monoclonal targets CD3

Clone ID: LN10

Antibody ID: AB_2890105

Vendor: ZSGB-Bio

Catalog Number: ZM-0417

Record Creation Time: 20250820T011523+0000

Record Last Update: 20250820T102653+0000

Ratings and Alerts

No rating or validation information has been found for CD3.

No alerts have been found for CD3.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at ASWG .

He C, et al. (2026) RNF138 promotes cisplatin resistance and PD-L1-mediated immune evasion via JAK2/STAT3 activation in nasopharyngeal carcinoma. Cell reports, 45(6), 117547.

Liu ZY, et al. (2025) Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy. Immunity, 58(6), 1572.

Tang J, et al. (2025) Protein-based classification reveals an immune-hot subtype in IDH mutant astrocytoma with worse prognosis. Cancer cell.

Wang H, et al. (2024) Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. Med (New York, N.Y.), 5(10), 1237.

Lin J, et al. (2023) Fas/FasL and Complement Activation are Associated with Chronic Active Epstein-Barr Virus Hepatitis. Journal of clinical and translational hepatology, 11(3), 540.

Duan J, et al. (2023) Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma. Cell reports. Medicine, 4(12), 101302.

Wu RQ, et al. (2023) Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma. Immunity, 56(1), 180.